Ldl-c Levels In Secondary Prevention: The Lower The Better and The Sooner The Better

Ischemic heart disease continues to be the leading cause of death worldwide. Low-density lipoproteins cholesterol (LDL-c) is the main responsible factor in its pathophysiology. Despite the great farmacological advance in lipid-lowering treatments (estatins, ezetimibe, PCSK9 inhibitors and those that remain to come bempedoic acid and inclisiran) most of our patients in secondary prevention present LDL-c levels over the recommended by the Clinical Practice Guidelines. For this reason, we developed a specific program in an attempt to achieve the goal of lowering LDL-c the lower and the sooner the better.